{
    "nct_id": "NCT06812052",
    "official_title": "Prospective Phase I Trial of Hypofractionated Radiation Therapy in Retroperitoneal Sarcoma",
    "inclusion_criteria": "* Participants must have a histologically confirmed STS of the retroperitoneal space or infra-peritoneal spaces of pelvis\n* Participant must have radiologically measurable disease (RECIST 1.1), as confirmed by abdomino-pelvic CT or MRI\n* Participant must have primary, locally recurrent, or metastatic disease requiring treatment of the retroperitoneal mass\n* Tumor must be suitable for radiotherapy and surgery based on pre-treatment CT scan/MRI in multidisciplinary discussion with surgeon and radiation oncologist (anticipated macroscopically complete resection, R0/R1 resection)\n* Age: 18 years or older\n* ECOG performance status ≤2\n* Absence of history of bowel obstruction, mesenteric ischemia, or severe chronic inflammatory bowel disease.\n* Normal renal function (calculated creatinine clearance ≥50 mL/min)\n* Normal bone marrow and hepatic function (white blood cell count ≥2·5 × 10⁹ cells per L, platelet count ≥80 × 10⁹ cells per L, and total bilirubin <2 times upper limit of normal)\n* Women of child-bearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment\n* Patients capable of childbearing/reproductive potential should use adequate contraception\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Sarcoma originating from bone structure, abdominal or gynecological viscera\n* Any of the following histological subtypes: gastrointestinal stromal tumor, rhabdomyosarcoma, primitive neuroectodermal tumor or other small round blue cell sarcoma, osteosarcoma, chondrosarcoma, aggressive fibromatosis, or sarcomatoid or metastatic carcinoma\n* Prior RT to the RPS\n* Prior abdominal or pelvic irradiation for other prior malignancy or other disease\n* Prior different invasive malignancy may be eligible per the discretion of the treating investigator and review by the Principal Investigator (PI)\n* Prior chemotherapy or immunotherapy within 6 weeks of start of RT\n* Pregnant women are excluded from this study because RT has the potential for teratogenic or abortifacient effects.\n* HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for increased sensitivity to RT",
    "miscellaneous_criteria": ""
}